ProfileGDS5678 / 1418074_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 73% 73% 75% 79% 74% 74% 73% 72% 72% 74% 74% 73% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7044373
GSM967853U87-EV human glioblastoma xenograft - Control 24.7044673
GSM967854U87-EV human glioblastoma xenograft - Control 34.7211773
GSM967855U87-EV human glioblastoma xenograft - Control 45.0803575
GSM967856U87-EV human glioblastoma xenograft - Control 55.5781279
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7930774
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.711174
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6331273
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6419972
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6528272
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7824274
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8678374
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6687973
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6860573